HIV Infections Clinical Trial
Official title:
A Multilevel HIV Prevention Strategy for High-Risk Youth
This study will evaluate the joint and separate effectiveness of two HIV/STD prevention programs in providing protection against acquiring STDs and maintaining safer sex behavior.
Approximately 25% of the new HIV cases in the United States each year occur among
adolescents. Although African American teens make up only 15% of the adolescent population
in the U.S., they account for about two thirds of new AIDS cases among teens. An Atlanta,
Georgia study involving a population composed primarily of urban African American teens
demonstrated that few of the teens who tested positive for HIV were aware of the risks
involved in sexual activity. Because of this population's increased risk for contracting HIV
and other STDs, prevention programs that specifically target African American teens are
necessary. This study will evaluate the joint and separate effectiveness of two HIV/STD
prevention programs, small group training and mass media messages, in providing protection
against acquiring STDs and maintaining safer sex behavior.
African American adolescents will be recruited for this single-blind, 18-month study through
community-based organizations in four different cities. All participants will first complete
a computer-administered survey to assess sexual attitudes, beliefs, and behaviors. They will
also provide a urine sample for STD testing. Following these baseline assessments,
participants will be randomly assigned to either the Focus on Youth (FOY) HIV prevention
program or the Promoting Health Among Teens general health intervention. Both programs will
involve eight 1-hour small group sessions that will occur over three Saturdays. Participants
in the FOY program will learn safe sex and abstinence skills. Participants in the Promoting
Health Among Teens intervention will receive general health information about diet,
substance use, and appropriate screening for common health conditions other than STDs. All
participants who test positive for an STD during the study will receive treatment. Follow-up
assessments will occur at Months 6, 12, and 18 post-intervention to determine program
effectiveness.
The second prevention program, mass media messages, will be administered among all
participating African American teens in one of the two participating Northern cities and one
of the two participating Southern cities. Cities that will receive the media intervention
will be randomly selected. The other city in each pair will serve as a control city.
Tailored HIV/STD prevention messages will be delivered through local mass media. Telephone
interviews will be conducted over a 34-month period among 900 randomly selected teens from
both media and non-media cities to assess community-wide effectiveness of the program.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |